Promethazine: Difference between revisions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Pharmacopedia: remove contraindications parameter |
MDElliottMD (talk | contribs) parser-claude: Promethazine MedTemplate refill, Top 300 stub upgrade |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Promethazine (hydrochloride) | ||
| brand | | brand = Phenergan, Promethegan (suppositories) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Antihistamines|First-generation antihistamine]], [[:Category:Phenothiazines|Phenothiazine]], [[:Category:Antiemetics|Antiemetic]] | ||
| | | uses = <vote slug="allergic-conditions-use">Allergic conditions (FDA)</vote>, <vote slug="motion-sickness-use">Motion sickness (FDA)</vote>, <vote slug="nausea-vomiting-broad-use">Nausea and vomiting from various causes (FDA; postoperative, chemotherapy, hyperemesis gravidarum, motion sickness)</vote>, <vote slug="preoperative-sedation-use">Preoperative sedation (FDA)</vote>, <vote slug="acute-migraine-adjunct-use">Acute migraine adjunct (off-label)</vote> | ||
| | | starting_dose = Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' | ||
| | | preparations = Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL | ||
| | | fda_max = 100 mg/day (adult) | ||
| | | pill_id = | ||
| routes | | routes = Oral, IM, IV (with caution), rectal | ||
| onset | | onset = 20 minutes (oral); 5 minutes (IV) | ||
| duration | | duration = 4-6 hours | ||
| halflife | | halflife = 12-15 hours<ref name="phenergan-label">FDA Prescribing Information, Phenergan (promethazine hydrochloride), Pfizer/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/007935s039lbl.pdf</ref> | ||
| bioavailability = ~25% (oral, with extensive first-pass)<ref name="phenergan-label" /> | |||
| pregnancy = Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data<ref name="phenergan-label" /> | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries two FDA '''Boxed Warnings''': (1) severe tissue injury including gangrene with IV administration, prompting recommendation for IM over IV use; (2) respiratory depression and death in children under 2 years, contraindicating use in that age group<ref name="phenergan-label" /> | |||
| | | mechanism = <vote slug="promethazine-mech-claim">'''Phenothiazine''' chemistry, sharing the receptor profile with the typical neuroleptics but used at lower doses and primarily for antihistamine and antiemetic effect rather than neuroleptic effect. Strong H1 antihistamine activity, moderate D2 antagonism (the antiemetic mechanism via chemoreceptor trigger zone in the area postrema), moderate muscarinic antagonism, and α1-adrenergic antagonism.</vote> Extrapyramidal symptoms (acute dystonia, akathisia) can occur at high doses or with chronic use, reflecting the phenothiazine D2 activity. The contraindication in children under 2 years follows fatal respiratory depression reports; the IV caution follows reports of severe tissue necrosis from extravasation despite proper technique<ref name="phenergan-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Antihistamines]] | [[Category:Antihistamines]] | ||
[[Category:Antiemetics]] | |||
[[Category:Phenothiazines]] | |||
Latest revision as of 07:26, 23 May 2026
Promethazine (hydrochloride)
Phenergan, Promethegan (suppositories)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Allergic conditions (FDA)0, Motion sickness (FDA)0, Nausea and vomiting from various causes (FDA; postoperative, chemotherapy, hyperemesis gravidarum, motion sickness)0, Preoperative sedation (FDA)0, Acute migraine adjunct (off-label)0
Pharmacy
Starting dose
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. Pediatric <2 years: contraindicated
Preparations
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL
US FDA Max
100 mg/day (adult)
Pharmacology
Routes
Oral, IM, IV (with caution), rectal
Onset
20 minutes (oral); 5 minutes (IV)
Duration
4-6 hours
Half-life
12-15 hours[1]
Bioavailability
~25% (oral, with extensive first-pass)[1]
Pregnancy
Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data[1]
Legal status
Purported mechanism
Phenothiazine chemistry, sharing the receptor profile with the typical neuroleptics but used at lower doses and primarily for antihistamine and antiemetic effect rather than neuroleptic effect. Strong H1 antihistamine activity, moderate D2 antagonism (the antiemetic mechanism via chemoreceptor trigger zone in the area postrema), moderate muscarinic antagonism, and α1-adrenergic antagonism.0 Extrapyramidal symptoms (acute dystonia, akathisia) can occur at high doses or with chronic use, reflecting the phenothiazine D2 activity. The contraindication in children under 2 years follows fatal respiratory depression reports; the IV caution follows reports of severe tissue necrosis from extravasation despite proper technique[1].